Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Quest Diagnostics Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52, while Quest Diagnostics Inc trades at $204.95 (market cap $22.80B). The key difference: Quest Diagnostics Inc pays a 1.67% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| BIL | DGX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $216.02 |
52-Week Low | $91.27 | $166.42 |
Market Cap | — | $22.80B |
Enterprise Value | — | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.50 with no recent price movement. Technical indicators show a bearish trend, with moving averages signaling sell pressure and oscillators neutral. The ETF maintains consistent dividend payments of $0.27 per share. Market sentiment is influenced by Federal Reserve rate hike speculation and competition among cash ETFs, as noted in recent financial news.
The outlook for BIL hinges on interest rate trends, with potential upside if the Fed hikes rates, boosting short-term Treasury yields. Risks include prolonged low-rate environments and investor shifts to higher-yielding alternatives. Current technical weakness suggests caution, but the ETF's stability and dividends offer defensive appeal in volatile markets.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
